宝莱特(300246) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥276,904,423.64, a decrease of 14.71% compared to the same period last year[2]. - The net profit attributable to shareholders was ¥16,652,530.73, down 77.75% year-on-year[2]. - The basic earnings per share were ¥0.1140, reflecting a decline of 77.75% compared to the previous year[2]. - The company achieved operating revenue of RMB 783.43 million, a year-on-year decrease of 28.88%[10]. - Net profit attributable to shareholders was RMB 69.40 million, down 77.96% year-on-year[10]. - Total operating revenue for the third quarter was CNY 783,429,137.12, a decrease from CNY 1,101,511,539.90 in the previous period[21]. - Net profit for the third quarter was CNY 69,702,953.84, down from CNY 322,204,103.25 in the same period last year[22]. - The net profit attributable to the parent company for Q3 2021 was ¥69,395,742.10, a decrease from ¥314,873,258.79 in the same period last year, representing a decline of approximately 78%[23]. - The total comprehensive income attributable to the parent company for Q3 2021 was ¥70,146,525.24, compared to ¥314,859,948.10 in the previous year, indicating a significant drop of about 78%[23]. - The basic and diluted earnings per share for Q3 2021 were both ¥0.4750, down from ¥2.1554 in the same period last year, reflecting a decrease of approximately 78%[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,705,028,246.22, an increase of 6.09% from the end of the previous year[2]. - Total assets increased to CNY 1,705,028,246.22 from CNY 1,607,164,079.53[19]. - Current liabilities rose to CNY 459,420,235.55 from CNY 394,650,575.02[19]. - Non-current liabilities increased to CNY 220,560,813.20 from CNY 179,681,496.40[19]. - Total liabilities amounted to CNY 679,981,048.75, up from CNY 574,332,071.42[19]. - Total equity decreased slightly to CNY 1,025,047,197.47 from CNY 1,032,832,008.11[19]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥62,602,875.04, down 82.56% year-on-year[2]. - Cash flow from operating activities for Q3 2021 was ¥62,602,875.04, a decrease of about 82% compared to ¥358,925,527.54 in Q3 2020[25]. - Cash flow from investing activities for Q3 2021 resulted in a net outflow of ¥118,117,940.16, worsening from a net outflow of ¥53,933,479.85 in the same period last year[26]. - Cash flow from financing activities for Q3 2021 generated a net inflow of ¥5,088,425.36, a significant decrease from ¥92,553,760.50 in Q3 2020[26]. - The total cash and cash equivalents at the end of Q3 2021 were ¥374,286,764.42, down from ¥539,433,776.42 at the end of Q3 2020, indicating a decline of approximately 31%[26]. - The company received cash from sales of goods and services amounting to ¥814,636,484.47 in Q3 2021, a decrease of about 29% from ¥1,151,875,719.40 in the same period last year[25]. - The company reported cash received from tax refunds of ¥18,412,095.24 in Q3 2021, slightly down from ¥21,528,878.69 in Q3 2020[25]. - The company’s cash outflow for employee compensation in Q3 2021 was ¥131,282,134.41, an increase from ¥89,778,237.05 in the same period last year, reflecting a rise of approximately 46%[25]. Investments and Capital - The company reported a significant increase in other receivables, which rose by 231.77% to ¥29,173,410.43 due to payments for equity acquisition guarantees[5]. - The company’s long-term equity investments increased by 131.51% to ¥8,092,228.93, attributed to capital increases in significant investees[5]. - Short-term borrowings increased by 70.86% to ¥133,785,700.00, reflecting a rise in bank loans[5]. - The company invested RMB 5 million to acquire a 19.38% stake in Suzhou Tongkang Medical Technology Co., Ltd.[15]. - An additional RMB 20 million was allocated to increase the registered capital of its wholly-owned subsidiary, Nanchang Baolait Medical Technology Co., Ltd., from RMB 50 million to RMB 70 million[15]. - The company plans to raise up to RMB 540 million through a private placement of shares, pending approval from the China Securities Regulatory Commission[12]. Business Strategy and Market Presence - The company is focusing on establishing a comprehensive ecosystem in the blood dialysis field while consolidating its medical monitoring equipment business[10]. - The company has enhanced its overseas market presence, particularly in response to the COVID-19 pandemic, improving brand recognition and reputation[11]. - The company continues to invest in high-end equipment and high-value-added product development to strengthen its market position[10]. - The company received three medical device registration certificates for its products, enhancing its competitive edge in health monitoring and renal medical fields[11]. Expenses - The company’s sales expenses decreased by 38.31% to ¥70,753,863.08 due to a reclassification of transportation costs[5]. - The income tax expense for the year-to-date was ¥12,091,873.56, a decrease of 79.55% compared to the previous year[6]. - Research and development expenses increased to CNY 46,992,755.18 from CNY 36,238,162.68[22].